Loperamide potentiates doxorubicin sensitivity in triple-negative breast cancer cells by targeting MDR1 and JNK and suppressing mTOR and Bcl-2: In vitro and molecular docking study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of biochemical and molecular toxicology"
DOI: 10.1002/jbt.22938
Abstract: Multidrug resistance (MDR) is the leading cause of treatment failure in triple-negative breast cancer (TNBC) patients treated with doxorubicin (DXR). We aimed to investigate the potential of the antidiarrheal drug Loperamide (LPR) in sensitizing TNBC… read more here.
Keywords: negative breast; breast cancer; mtor bcl; mdr1 ... See more keywords